11:29 AM EDT, 10/18/2024 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Friday that its veterinary partner Vetbiolix reported positive final results from the clinical study of Piclidenoson in dog patients with osteoarthritis, with the study achieving its primary and secondary endpoints.

"The final data from the osteoarthritis study are very encouraging," said Sari Fishman, vice president of business Development at Can-Fite. "This veterinary indication offers Can-Fite the opportunity to get Piclidenoson onto the market faster to benefit canine, and potentially contribute to near-term revenues."

Vetbiolix has exercised its option for an in-license agreement with Can-Fite and will pay an upfront payment, milestone payments and royalties upon regulatory approval, bringing projected income of $325 million to Can-Fite over the next 10 years, the firm said.

Price: 2.76, Change: +0.06, Percent Change: +2.33